FY2026 Earnings Estimate for BEAM Issued By HC Wainwright

Beam Therapeutics Inc. (NASDAQ:BEAM) – Analysts at HC Wainwright issued their FY2026 earnings estimates for shares of Beam Therapeutics in a research report issued to clients and investors on Monday, February 3rd. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings of ($3.30) per share for the year. HC Wainwright has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. HC Wainwright also issued estimates for Beam Therapeutics’ FY2027 earnings at ($3.00) EPS and FY2028 earnings at ($1.91) EPS.

BEAM has been the topic of several other research reports. Leerink Partners upgraded Beam Therapeutics from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $27.00 to $39.00 in a report on Wednesday, November 6th. Leerink Partnrs raised Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. Wedbush restated an “outperform” rating and set a $57.00 target price on shares of Beam Therapeutics in a research note on Monday, January 13th. Cantor Fitzgerald raised shares of Beam Therapeutics from a “neutral” rating to an “overweight” rating in a report on Wednesday, January 29th. Finally, Scotiabank assumed coverage on shares of Beam Therapeutics in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $24.00 target price for the company. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Beam Therapeutics has a consensus rating of “Buy” and an average target price of $47.67.

Beam Therapeutics Price Performance

NASDAQ BEAM opened at $25.75 on Wednesday. The firm has a 50 day simple moving average of $26.48 and a 200-day simple moving average of $25.76. Beam Therapeutics has a one year low of $20.84 and a one year high of $49.50.

Beam Therapeutics (NASDAQ:BEAM) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.01). Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The firm had revenue of $14.30 million during the quarter, compared to analyst estimates of $14.52 million. During the same period in the previous year, the firm posted ($1.22) earnings per share. The company’s quarterly revenue was down 16.9% compared to the same quarter last year.

Hedge Funds Weigh In On Beam Therapeutics

A number of large investors have recently bought and sold shares of the stock. Blue Trust Inc. raised its holdings in Beam Therapeutics by 84.0% in the third quarter. Blue Trust Inc. now owns 3,135 shares of the company’s stock valued at $73,000 after buying an additional 1,431 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Beam Therapeutics by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,981 shares of the company’s stock worth $75,000 after acquiring an additional 524 shares in the last quarter. Arcadia Investment Management Corp MI purchased a new position in shares of Beam Therapeutics in the 3rd quarter valued at $98,000. KBC Group NV lifted its holdings in shares of Beam Therapeutics by 103.2% during the 4th quarter. KBC Group NV now owns 4,143 shares of the company’s stock valued at $103,000 after acquiring an additional 2,104 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in Beam Therapeutics by 13.3% during the 3rd quarter. GAMMA Investing LLC now owns 4,620 shares of the company’s stock worth $113,000 after purchasing an additional 544 shares during the period. Hedge funds and other institutional investors own 99.68% of the company’s stock.

Insiders Place Their Bets

In other news, CEO John M. Evans sold 30,000 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $26.75, for a total transaction of $802,500.00. Following the sale, the chief executive officer now owns 908,659 shares in the company, valued at $24,306,628.25. This trade represents a 3.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Christine Bellon sold 1,241 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total value of $30,627.88. Following the completion of the transaction, the insider now owns 102,968 shares of the company’s stock, valued at $2,541,250.24. The trade was a 1.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.20% of the stock is currently owned by company insiders.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.